Trial Profile
A Phase IIb, Double-blind, Randomized, Mono-center, Placebo-controlled Study With Crossover Design Characterizing the Effects of Prolonged-release Fampridine Treatment on Ambulatory Function in Patients With Multiple Sclerosis Using Detailed Gait Analysis Based on Kinematic and Kinetic Parameters
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Jun 2021
Price :
$35
*
At a glance
- Drugs Fampridine (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms FAMPKIN
- 01 Feb 2017 Results of extension study, assessing long term eficacy of famopridine published in the Neurology.
- 05 Nov 2014 Planned End Date changed from 1 Apr 2013 to 1 Apr 2017 according to CliniclaTrials.gov record.
- 05 Nov 2014 Planned primary completion date changed from 1 Apr 2013 to 1 Apr 2017 according to ClinicalTrials.gov record.